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Introduction 
Frontal fibrosing alopecia (FFA) is a primary cicatricial 
alopecia that presents as progressive band-like hair 
loss involving the frontotemporal hairline, eyebrows, 
and body hair and is predominantly seen in 
postmenopausal women. Frontal fibrosing alopecia 
is considered a clinical variant of lichen planopilaris 
(LPP), as both have a similar appearance on 
histology. In both FFA and LPP, there is a 
perifollicular lymphocytic infiltrate, concentric 
fibrosis, and apoptosis of keratinocytes. The 
mechanism of pathogenesis of FFA is unknown. 
However, several hypotheses exist, including 
antigen cross-reactivity [1], loss of immune privilege 
[2], and defective PPAR-gamma activity [3]. All these 
proposed mechanisms share the same principle of 
pathogenesis: that activation of T lymphocyte-
mediated destruction of keratinocytes in the hair 
follicle bulge leads to obliteration of the hair follicle 
over time. 
Ustekinumab is a monoclonal antibody approved for 
use in psoriasis, psoriatic arthritis, and Crohn disease. 
It targets the common p40 subunit of cytokines IL-12 
and IL-23. Binding this subunit inhibits 
differentiation of CD4+ helper T lymphocytes 
towards Th1 and Th17 phenotypes, which are reliant 
on IL-12 and IL-23 signaling, respectively. Psoriasis is 
a Th17-driven disease; thus, ustekinumab is an 
effective therapy for psoriasis. However, its effects on 
FFA and inflammation in the hair follicle have not 
been studied. 
 
Case Synopsis 
A 62-year-old woman with well-controlled psoriasis 
treated for 5 years with ustekinumab 90mg 
subcutaneously every 12 weeks presented with loss 
of eyebrows, fronto-temporal patchy hair loss, 
erythema, and pruritus (Figure 1). A scalp biopsy 
showed a perifollicular lichenoid infiltrate involving 
the upper segment of the hair follicle, concentric 
perifollicular fibrosis, and loss of sebaceous glands 
(Figure 2). Horizontal sectioning also showed a 
reduced number of terminal and vellus hair follicles, 
along with a reduced anagen-to-catagen/telogen 
ratio of 1:1 (reference 15.5:1) and elevated telogen 
fraction of 0.5 (reference 0-0.15). A diagnosis of 
frontal fibrosing alopecia was made. 
The patient was subsequently treated with 
numerous therapies over the course of three years, 
Abstract 
The mechanism underlying frontal fibrosing alopecia 
(FFA) is unknown, but proposed mechanisms share 
commonality of T cell-mediated destruction of the 
hair follicle bulge. IL-12 and IL-23 are key cytokines 
involved in CD4 T cell differentiation towards Th1 and 
Th17 phenotypes. We present a 62-year-old woman 
who developed persistent FFA while on ustekinumab 
for treatment of preexisting psoriasis. This case 
presents evidence against Th1 and Th17 pathways as 
essential to pathogenesis in FFA. This case also 
suggests that IL-12 and IL-23 inhibition is ineffective 
for this form of scarring alopecia. 
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including multiple intralesional triamcinolone 
injections, minocycline 100mg twice daily orally for 
over one year, hydroxychloroquine 200mg twice 
daily orally for 6 months, twice daily topical 
fluocinonide 0.05% solution, once daily topical 
tacrolimus 0.1% solution, once daily topical 
clindamycin to the scalp, daily minoxidil foam, and 
finasteride. Despite these therapies, the patient 
continued to have mild recession of the frontal 
hairline, progressing from 11cm to 13cm measured 
at her midline, from the glabella. Her left temporal 
hairline also continued to recede, from 9 to 10cm 
over the course of three years. Ustekinumab therapy 
for psoriasis was continued during these three years. 
 
Case Discussion 
In our case, we observed the onset and progression 
of FFA while incidentally on ustekinumab in addition 
to typical FFA treatments. Currently, no systematic 
studies of FFA treatment have been performed, but 
a small case series showed limited efficacy of topical 
corticosteroids and minoxidil as observed in our 
patient [4]. One case report noted that initiation of 
ustekinumab with active LPP was ineffective at 
preventing progression [5]. 
The initiation of FFA while on an anti-IL12/23 p40 
monoclonal antibody suggests that the Th1 and 
Th17 pathways do not play a major role in FFA, as FFA 
developed despite inhibiting these pathways. 
Histologic characterization of LPP shows a 
predominance of effector CD8+ lymphocytes with 
CD8:CD4 ratios of 1.2:1 versus 0.4:1 in normal 
controls, indicating the importance of CD8+ T cells in 
LPP [2]. The lymphocytic predominance with an 
absence of neutrophils in LPP also supports the idea 
that the Th17 pathway is dispensable, in contrast 
with psoriasis in which neutrophilic infiltrate is 
present. These findings together suggest a Th1- and 
Th17-independent mechanism in FFA. 
Several possible mechanisms may explain our 
observations. Paradoxical activation of pro-
inflammatory mediators, such as IL-17, though IL-12 
inhibition may serve as a potential mechanism [6]; 
the progression of FFA in our patient while on 
ustekinumab therapy may be suggestive. Another 
theory postulates involvement of MHC-I 
upregulation in keratinocytes, leading to activation 
of CD8+ T lymphocytes, which may bypass Th1/17 
inhibition [2]. Theoretically, cross-presentation by 
dendritic cells could also directly activate CD8+ T 
cells and elicit a cytotoxic T lymphocyte response, 
which would rely less on Th1/17 pathway activation. 
Although androgenetic alopecia and telogen 
effluvium, two hair loss disorders whose 
pathogenesis have no known inflammatory 
Figure 1: Clinical image of frontal fibrosing alopecia. Progressive 
alopecia over frontotemporal hairline (left) and one year later 
(right) while continuing ustekinumab therapy. 
 
Figure 2: Representative histology of frontal fibrosing alopecia. 
Lichenoid inflammation with localized infiltrate in peri-isthmus 
(bulge) region. H&E, 200x. 
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component, have been noted to persist in patients 
while on ustekinumab, this is the first case, to our 
knowledge, noted with FFA onset and persistence 
during ustekinumab treatment. Other authors have 
postulated that the pathophysiology behind FFA is 
analogous to alopecia areata (AA), with inflamma-
tion localized to the bulge in FFA rather than the 
bulb in AA [7]. Alopecia areata has been mechanis-
tically linked to the Th1 pathway, with case studies of 
successful treatment with ustekinumab. These case 
series together support the possibility that FFA and 
AA may have differences in their pathophysiology.  
Our case suggests that although there is no clear link 
between the Th1 and Th17 pathway and its 
pathogenesis in FFA, it appears that inhibition of 
these pathways are not effective in treatment or 
prevention of the onset of FFA. Further observations 
and comparisons of LPP or FFA occurring in patients 
while on biologic medications of differing targets 
would be required to establish this association. 
 
Potential conflicts of interest 
The authors declare no conflicts of interests. 
 
 
References 
1. Shiohara T, Mizukawa Y, Takahashi R, Kano Y. Pathomechanisms 
of lichen planus autoimmunity elicited by cross-reactive T cells. 
Curr Dir Autoimmun. 2008;10:206–226. [PMID: 18460888]. 
2. Harries MJ, Meyer K, Chaudhry I, et al. Lichen planopilaris is 
characterized by immune privilege collapse of the hair follicle’s 
epithelial stem cell niche. J Pathol. 2013;231:236–247. [PMID: 
23788005]. 
3. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-
specific PPARγ deletion causes scarring alopecia. J Invest Dermatol 
2009;129:1243–1257. [PMID: 19052558]. 
4. Rácz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HAM. 
Treatment of frontal fibrosing alopecia and lichen planopilaris: a 
systematic review. J Eur Acad Dermatol Venereol. 2013;27:1461–
1470. [PMID: 23531029]. 
5. Webster G. Failure of lichen planopilaris to respond to 
ustekinumab. Dermatol Online J. 2015;21(11). [PMID: 26632941]. 
6. Hoeve MA, Savage NDL, de Boer T, et al. Divergent effects of IL-12 
and IL-23 on the production of IL-17 by human T cells. Eur J 
Immunol. 2006;36:661–670. [PMID: 16482511]. 
7. Tziotzios C, Stefanato CM, Fenton DA, Simpson MA, McGrath JA. 
Frontal fibrosing alopecia: reflections and hypotheses on 
aetiology and pathogenesis. Exp Dermatol. 2016;25:847–852. 
[PMID: 27198858]. 
 
